Market overview
The global specialty pharmacy market is worth USD 523 bn in 2026 and is forecast to reach USD 1.2 tn by 2036, growing at a 8.5% CAGR. United States is the largest country market and Autoimmune and inflammatory is the largest by therapy area segment.
| Scope | Pharmacies that dispense high-cost specialty drugs for cancer, rare, autoimmune and other complex conditions, with clinical support and patient programmes. |
|---|---|
| Industry | Healthcare |
| Value 2025 | USD 480 bn |
| Value 2026 | USD 523 bn |
| Value 2036 | USD 1.2 tn |
| CAGR 2026-2036 | 8.5% |
| Volume 2026 | 169 million prescriptions |
| Volume 2036 | 285 million prescriptions |
| Average price 2026 | USD 3,090 per prescription |
| Report price | Starts from USD 1,999 |
| Published | November 2026 |
Request a free sample of this report
Specialty Pharmacy market size and forecast, 2026-2036
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Year | Market value |
|---|---|
| 2026 | USD 523 bn |
| 2027 | USD 568 bn |
| 2028 | USD 616 bn |
| 2029 | USD 668 bn |
| 2030 | USD 725 bn |
| 2031 | USD 787 bn |
| 2032 | USD 854 bn |
| 2033 | USD 926 bn |
| 2034 | USD 1.0 tn |
| 2035 | USD 1.1 tn |
| 2036 | USD 1.2 tn |
Specialty Pharmacy market segmentation
By therapy area
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Oncology | 22.0% | 22.7% | USD 115 bn | 8.8% |
| Autoimmune and inflammatory | 28.0% | 26.4% | USD 146 bn | 7.8% |
| Rare and genetic diseases | 12.0% | 14.9% | USD 62.8 bn | 10.8% |
| Infectious disease and HIV | 10.0% | 7.1% | USD 52.3 bn | 4.9% |
| Neurology and other | 28.0% | 28.9% | USD 146 bn | 8.8% |
By ownership
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Health plan and PBM owned | 62.0% | 59.5% | USD 324 bn | 8.1% |
| Retail chain owned | 14.0% | 12.8% | USD 73.2 bn | 7.5% |
| Independent and infusion | 24.0% | 27.7% | USD 126 bn | 10.1% |
By drug route
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Oral specialty | 40.0% | 36.0% | USD 209 bn | 7.4% |
| Injectable and infusion | 46.0% | 50.0% | USD 241 bn | 9.4% |
| Cell and gene therapy | 14.0% | 14.0% | USD 73.2 bn | 8.5% |
By service
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Dispensing | 60.0% | 56.0% | USD 314 bn | 7.8% |
| Patient support and adherence | 18.0% | 20.0% | USD 94.2 bn | 9.7% |
| Infusion and clinic services | 22.0% | 24.0% | USD 115 bn | 9.4% |
By payer
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Commercial | 46.0% | 44.0% | USD 241 bn | 8.0% |
| Medicare and Medicaid | 42.0% | 44.0% | USD 220 bn | 9.0% |
| Cash and manufacturer | 12.0% | 12.0% | USD 62.8 bn | 8.5% |
Top 25 countries for specialty pharmacy by revenue
Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 96.5% of 2026 revenue and the 25 countries below together hold 98.6%.
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| # | Country | Value 2026 | Share 2026 | Value 2036 | CAGR 2026-36 |
|---|---|---|---|---|---|
| 1 | United States | USD 377 bn | 72.0% | USD 877 bn | 8.8% |
| 2 | Germany | USD 20.9 bn | 4.0% | USD 40.2 bn | 6.8% |
| 3 | United Kingdom | USD 15.7 bn | 3.0% | USD 30.8 bn | 7.0% |
| 4 | France | USD 15.7 bn | 3.0% | USD 28.4 bn | 6.1% |
| 5 | Japan | USD 15.7 bn | 3.0% | USD 27.2 bn | 5.7% |
| 6 | Canada | USD 15.7 bn | 3.0% | USD 33.1 bn | 7.8% |
| 7 | China | USD 15.7 bn | 3.0% | USD 48.5 bn | 11.9% |
| 8 | Italy | USD 10.5 bn | 2.0% | USD 18.9 bn | 6.1% |
| 9 | Spain | USD 10.5 bn | 2.0% | USD 18.9 bn | 6.1% |
| 10 | Brazil | USD 7.8 bn | 1.5% | USD 17.7 bn | 8.5% |
| 11 | Switzerland | USD 2.5 bn | 0.5% | USD 5.0 bn | 7.3% |
| 12 | Netherlands | USD 1.5 bn | 0.3% | USD 3.0 bn | 7.3% |
| 13 | Australia | USD 1.0 bn | 0.2% | USD 2.2 bn | 7.9% |
| 14 | South Korea | USD 889 mn | 0.2% | USD 1.8 bn | 7.2% |
| 15 | India | USD 732 mn | 0.1% | USD 2.1 bn | 11.3% |
| 16 | Mexico | USD 628 mn | 0.1% | USD 1.9 bn | 11.7% |
| 17 | Belgium | USD 576 mn | 0.1% | USD 1.2 bn | 7.5% |
| 18 | Sweden | USD 523 mn | 0.1% | USD 1.1 bn | 7.4% |
| 19 | Russia | USD 471 mn | 0.09% | USD 946 mn | 7.2% |
| 20 | Saudi Arabia | USD 419 mn | 0.08% | USD 1.3 bn | 12.0% |
| 21 | Austria | USD 419 mn | 0.08% | USD 828 mn | 7.1% |
| 22 | Poland | USD 366 mn | 0.07% | USD 1.1 bn | 11.3% |
| 23 | Turkey | USD 366 mn | 0.07% | USD 1.1 bn | 11.3% |
| 24 | Denmark | USD 314 mn | 0.06% | USD 710 mn | 8.5% |
| 25 | Thailand | USD 314 mn | 0.06% | USD 946 mn | 11.7% |
| Rest of world | USD 7.3 bn | 1.4% | USD 17.5 bn | 9.1% |
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
Competitive landscape
Group 1: Global leaders
- CVS Health
- Cigna (Accredo)
- UnitedHealth Group (Optum Rx)
- Walgreens Boots Alliance
- Cencora
- McKesson
Group 2: Regional and specialist players
- Option Care Health
- Humana (CenterWell Pharmacy)
- Cardinal Health
- Elevance Health
- Onco360
- Soleo Health
- Avella Specialty Pharmacy
Group 3: Emerging and niche players
- Shields Health Solutions
- Trellis Rx
- ProCare Rx
Research methodology
Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the specialty pharmacy market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.
The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 8.5% is calculated from the resulting values.
The market is divided by therapy area, by ownership, by drug route, by service, by payer. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.
Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.
Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.
Frequently asked questions
How big is the specialty pharmacy market?
The global specialty pharmacy market is estimated at USD 480 bn in 2025 and USD 523 bn in 2026.
How fast will the specialty pharmacy market grow?
It is forecast to reach USD 1.2 tn by 2036, a compound annual growth rate of 8.5% from 2026, an increase of USD 660 bn.
Which country is the largest market for specialty pharmacy?
United States is the largest market by revenue at USD 377 bn in 2026, 72.0% of the global total. The three largest countries together hold 79.0%.
Which country is growing fastest?
Among the ten largest markets, China is growing fastest at 11.9% a year from 2026 to 2036.
Which specialty pharmacy segment is largest?
In the by therapy area split, Autoimmune and inflammatory is the largest segment with 28.0% of 2026 revenue.
Who are the leading specialty pharmacy companies?
Global leaders include CVS Health, Cigna (Accredo), UnitedHealth Group (Optum Rx), Walgreens Boots Alliance.
Need the full report?
Request a sample to see the structure, tables and country detail.
Request a free sampleRelated markets in Healthcare
- NutraceuticalUSD 516 bn · 7.5% CAGR
- Mental Health ServicesUSD 511 bn · 6.0% CAGR
- Hospital PharmacyUSD 509 bn · 6.3% CAGR
- BiologicsUSD 508 bn · 8.0% CAGR
- TabletUSD 580 bn · 5.5% CAGR
- Generic DrugsUSD 462 bn · 5.0% CAGR
- Sterile InjectableUSD 454 bn · 8.5% CAGR
- Home HealthcareUSD 410 bn · 8.0% CAGR